Trade BEAM stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Beam Therapeutics Inc. (BEAM) is trading at US$27.79, up 5.55% today as of Nov 4, 16:00 EST. The company has a market capitalisation of US$3.07B. Over the past 52 weeks, BEAM has traded between US$20.23 and US$38.26. On Syfe you can trade BEAM with $0 commission and add it to your watchlist.
| Previous close | US$26.33 |
|---|---|
| Market cap | US$3.07B |
| 52-week range | US$20.23 – US$38.26 |
| Volume | 1.35M |
| Exchange | US |
Beam Therapeutics Inc.
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Year: 2020
Beam Therapeutics Inc. (BEAM) stock is trading at US$27.79, +5.55% from the previous close of US$26.33.
The market cap for Beam Therapeutics Inc. (BEAM) stock is approximately US$3.07B.
The 52-week high for Beam Therapeutics Inc. (BEAM) stock is US$38.26.
The 52-week low for Beam Therapeutics Inc. (BEAM) stock is US$20.23.
Beam Therapeutics Inc. (BEAM) does not currently pay a dividend.
Stay on top of BEAM
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
